Drug Trial Radar · NCT02974855
PF-06741086 Multiple Dose Study in Severe Hemophilia
Last checked: Nov 20, 2026Latest source record: Dec 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Mar 8, 2017
Primary completion
Dec 3, 2018
Study completion Dec 3, 2018
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 29, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of multiple subcutaneous and/or intravenous doses of PF-06741086 in subjects with severe hemophilia.
Conditions
- Hemophilia A or B
Interventions
PF-06741086Biological
PF-06741086 subcutaneous (SC) injection
PF-06741086Biological
PF-06741086 SC injection
PF-06741086Biological
PF-06741086 SC injection
PF-06741086Biological
PF-06741086 SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Study Day 1 to Day 113 Visit
- Number of Participants Discontinued From Study Due to TEAEsTime frame: Study Day 1 to Day 113 Visit
- Number of Participants With Abnormal Laboratory Findings-HematologyTime frame: Baseline to Study Day 113 Visit
- Number of Participants With Abnormal Laboratory Findings-Clinical ChemistryTime frame: Baseline to Study Day 113
- Number of Participants With Abnormal Laboratory Findings-UrinalysisTime frame: Baseline to Study Day 113 Visit
- Change From Baseline for Globulin by Dose CohortTime frame: Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.
- Change From Baseline for Prothrombin International Normalized Ratio (PT/INR) by Dose CohortTime frame: Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.
- Change From Baseline for Activated Partial Thromboplastin Time (aPTT) by Dose CohortTime frame: Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.
- Change From Baseline for Fibrinogen by Dose CohortTime frame: Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.
- Change From Baseline for Antithrombin III by Dose CohortTime frame: Baseline, Study Day 8, 15, 22 and 29.
- Change From Baseline for Troponin I by Dose CohortTime frame: Baseline, Study Day 8, 15, 22, 29, 57 and 85.
- Number of Participants With Vital Signs Data Meeting Pre-specified CriteriaTime frame: Baseline to Study Day 113 Visit
- Number of Participants With Electrocardiogram (ECG) Change Meeting Pre-specified CriteriaTime frame: Baseline to Study Day 29 Visit.
- Number of Participants With Clinically Significant Changes in Physical Examination FindingsTime frame: Baseline to Study Day 113 Visit
- Number of Participants With Infusion and Injection Site ReactionsTime frame: Baseline to Study Day 113 Visit
Locations
10 sites in 6 countries. Site status is shown where the registry gives one.
UC Denver Hemophilia and Thrombosis Center - Pharmacy
Aurora, Colorado
UC Denver Hemophilia and Thrombosis Center
Aurora, Colorado
Pharmacy
Chicago, Illinois
Rush University Medical Center
Chicago, Illinois
Hospital Dr. Sotero del Rio
Santiago, Chile
Klinicki bolnicki centar Zagreb
Zagreb, Croatia
Klinika Hematologii i Transplantologii Uniwersyteckie Centrum Kliniczne
Gdansk, Poland
Phoenix Pharma (Pty) Ltd
Port Elizabeth, Eastern Cape, South Africa
Haemophilia Comprehensive Care Centre
Johannesburg, Gauteng, South Africa
UniversitatsSpital Zurich, Klinik fur Hamatologie
Zurich, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.